Old drug, new hope: niclosamide combo tackles tough prostate cancer
NCT ID NCT03123978
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and best dose of adding niclosamide (a drug used for tapeworm infections) to standard hormone therapy (enzalutamide) in 6 men with advanced prostate cancer that no longer responds to hormone treatment. The goal was to see if the combination could be given safely and help control the cancer. The study was completed but did not involve a cure; patients continued on ongoing treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo tame resistant prostate cancer?
- Can a radioactive 'Smart Bomb' shrink resistant prostate tumors?
- New PET tracer could reveal hidden prostate cancer
- AI could predict which prostate cancers turn aggressive
- New hope for advanced bladder cancer? bevacizumab combo tested
- Intermittent fasting tested to ease radiation side effects in cancer patients